22 results about "Immunohistochemistry" patented technology

This invention discloses a breast cancer classification method based on Piezo1 expression. After obtaining tumor tissue samples from patients, the method detects the Piezo1 protein expression level using immunohistochemistry and classifies them into high-expression and low-expression types according to a validated scoring standard. This classification result guides individualized treatment, with high-expression patients recommended for treatment regimens including inhibitors of mechanotransmission pathways. By integrating tumor mechanotransmission characteristics into the clinical classification system, this invention can identify a subgroup of breast cancer driven by an abnormal mechanotransmission microenvironment that cannot be distinguished by traditional molecular classification. This not only improves and supplements the existing classification framework, making the understanding of breast cancer heterogeneity more comprehensive, but also more accurately predicts the invasiveness, metastasis potential, and poor prognostic risk of these patients.

1. Name of the product in this design: Fully Automatic Immunohistochemistry Independent Temperature Controlled Individual Drop Staining Machine (CNT310). 2. Purpose of this design: For staining samples before pathological analysis. 3. The key design feature of this product is its shape. 4. The image or photograph that best illustrates the design's key points: a 3D model.

This invention discloses an anti-MSLN antibody and its applications. The anti-MSLN antibody comprises a heavy chain variable region and a light chain variable region. The heavy chain variable region comprises HCDR1, HCDR2, and HCDR3, and the light chain variable region comprises LCDR1, LCDR2, and LCDR3. The amino acid sequences of HCDR1, HCDR2, and HCDR3 are shown in SEQ ID NO:7, 8, and 9, respectively; and the amino acid sequences of LCDR1, LCDR2, and LCDR3 are shown in SEQ ID NO:4, 5, and 6, respectively. The antibody provided by this invention has good affinity and specificity for MSLN antigens, effectively detecting target proteins in cells overexpressing MSLN. It can also be widely used as a core ingredient in the development of high-sensitivity MSLN detection kits such as ELISA, Western blotting, and immunohistochemistry.

This invention discloses the application of arginine-depleted engineered bacteria for the treatment of soft tissue sarcomas, including preliminary validation, obtaining qualified engineered bacteria SGR1, obtaining drug compositions and regimens, experimental conclusions, and clinical application promotion. During use, clinical soft tissue sarcoma samples are collected, including undifferentiated pleomorphic sarcoma, synovial sarcoma, and liposarcoma. Immunohistochemistry (IHC) is used to detect ASS1 protein expression, qPCR is used to detect ASS1 gene transcription levels, and the proportion of ASS1 deletion / low expression is statistically analyzed. Arginine auxotrophic sarcoma subpopulations are confirmed based on literature. Cells are cultured in arginine-containing or arginine-free media, and cell viability, colony formation, cell cycle, and apoptosis are detected. The sensitivity of ASS1-deficient cells to arginine deprivation is verified, and therapeutic targets are identified. The enzyme activity, substrate specificity, and immunogenicity of human ARG I / II, mycoplasma ADI, and Pseudomonas ADI are compared. High-activity, low-immunogenic enzymes or enzyme combinations (such as human ARG I + microbial ADI) are selected, and site-directed mutagenesis or codon optimization is performed on microbial ADI to increase expression levels.

This invention discloses an anti-MSLN antibody and its applications. The anti-MSLN antibody comprises a heavy chain variable region and a light chain variable region. The heavy chain variable region comprises HCDR1, HCDR2, and HCDR3, and the light chain variable region comprises LCDR1, LCDR2, and LCDR3. The amino acid sequences of HCDR1, HCDR2, and HCDR3 are shown in SEQ ID NO:7, 8, and 9, respectively; and the amino acid sequences of LCDR1, LCDR2, and LCDR3 are shown in SEQ ID NO:4, 5, and 6, respectively. The antibody provided by this invention has good affinity and specificity for MSLN antigens, effectively detecting target proteins in cells overexpressing MSLN. It can also be widely used as a core ingredient in the development of high-sensitivity MSLN detection kits such as ELISA, Western blotting, and immunohistochemistry.

This invention belongs to the field of biomedicine and tumor immunotherapy technology, specifically relating to a monoclonal antibody targeting the immune checkpoint molecule CD276 (B7-H3) and its applications. The applicant conducted immunization and screening work around the human CD276 antigen, selecting two representative monoclonal antibody clones, 2B2-1 and 5G4-2, from multiple candidate antibodies. The nucleotide and amino acid sequences of their heavy and light chain variable regions were determined, and their performance in flow cytometry, T-cell killing assays, immunohistochemistry, ELISA, and Biacore affinity assays was systematically evaluated. Experimental results show that the above antibodies can specifically recognize and bind to CD276, efficiently distinguish between CD276-high and low-expressing cells, and enhance the killing activity of T cells against CD276-high expressing tumor cells in an in vitro co-culture system. This provides an excellent antibody backbone for the subsequent construction of diagnostic kits, ADC drugs, or bispecific antibodies.

The application provides an incubation device for immunohistochemistry, a staining treatment all-in-one machine and a control method thereof. The device comprises a cabin body, a carrier and a condensation flow guide plate. The carrier is provided with a humidification flow channel, which is divided into multiple liquid accumulation pools by a liquid distribution baffle, and the overflow principle is used to ensure uniform humidity and inhibit liquid accumulation during movement. The condensation flow guide plate is provided with a heating surface and a condensation surface, the temperature of the condensation surface is controlled to be lower than the dew point, vapor is induced to condense on the condensation surface and is discharged to a waste liquid outlet through the flow guide surface, and condensate droplets are prevented from falling on the slide. A driving assembly drives the carrier to move between an incubation position and an operation position and drives the cabin door to move. The application combines zoned temperature control, induced condensation and physical directional flow guidance, solves the risk of sample dilution caused by random condensation of condensate in a high humidity environment, simplifies the overall structure of the machine and improves the automation integration degree.

This invention discloses the application of P4HB as a target in the preparation of therapeutic drugs for metastatic pleural and peritoneal effusions in multiple cancer types. Through combined single-cell transcriptomics and proteomics analysis, this invention revealed that P4HB is significantly overexpressed in metastatic pleural and peritoneal effusion lesions. Multiplex immunofluorescence and immunohistochemistry were used to perform in situ tissue validation in clinical samples of pleural and peritoneal effusions from breast cancer, lung cancer, gastric cancer, colorectal cancer, and ovarian cancer, clarifying the differential expression characteristics of P4HB in metastatic tumor cells and its correlation with poor prognosis. In patient-derived organoid models, targeting and inhibiting P4HB activity with small molecule inhibitors significantly reduced organoid growth capacity and survival rate, and showed a synergistic sensitizing effect on chemotherapeutic drugs. This invention reveals the use of P4HB as a therapeutic target for metastatic pleural and peritoneal effusions in multiple cancer types, providing a new target and direction for drug development in precision medicine.

The application discloses a PET tracer targeting carbonic anhydrase IX (CA IX) and a preparation method and application thereof. 68 The tracer is prepared from a DOTA-bis-sulfonamide precursor compound and GaCl3 reaction. The tracer has high hydrophilicity, excellent stability in vitro and in vivo, low uptake of non-target organs and is mainly excreted through the kidney. Micro-PET / CT imaging shows that the tumor uptake is linearly correlated with the CA IX protein expression level measured by immunohistochemistry. Acute toxicity experiments show that the tracer has good biological safety. The application further provides a radiopharmaceutical composition containing the tracer and application of the tracer in preparation of a PET imaging agent for diagnosing CA IX positive tumors. The tracer has the advantages of high labeling efficiency, low background interference, accurate quantification and potential integration of diagnosis and treatment, and is suitable for precise molecular imaging of CA IX high expression tumors such as clear cell renal cell carcinoma and colorectal cancer.

This application relates to the field of antibody technology, and discloses a CRP immunohistochemical antibody and its application. The antibody includes a heavy chain variable region and a light chain variable region. Combinations of the heavy chain variable region and the light chain variable region include: Combination 1: the heavy chain variable region contains the amino acid sequence shown in SEQ ID NO:2, and the light chain variable region contains the amino acid sequence shown in SEQ ID NO:4; or Combination 2: the heavy chain variable region contains the amino acid sequence shown in SEQ ID NO:6, and the light chain variable region contains the amino acid sequence shown in SEQ ID NO:8. The antibody of this application achieves precise localization by recognizing tumor cell-specific CRP conformations or post-translational modification epitopes. It specifically recognizes CRP expressed by tumor cells, completely avoiding interference from serum CRP and non-specific deposition in necrotic areas, and exhibits no background staining in normal tissues.

The application relates to the field of biological medicine, and particularly discloses a monoclonal antibody combined with human CD8 and a preparation method and application thereof. The antibody is obtained by combining single B cell sorting, gene cloning and mammalian cell expression technology after rabbit immunization of a CD8 polypeptide antigen, a New Zealand white rabbit is immunized by adopting a KLH coupled CD8 antigen polypeptide combined with a rapid immunoadjuvant, high-affinity antibody clones are obtained by single B cell sorting technology, and the antibody is prepared by recombination expression. The antibody is verified by ELISA and flow cytometry, has high titer and strong specificity, can effectively recognize human peripheral blood CD8+ T cells, and has a signal strength and a background signal-to-noise ratio which are significantly better than those of a traditional mouse-derived antibody. The application provides light and heavy chain variable region amino acid sequences of the antibody, realizes controllable preparation of the antibody and protection of intellectual property rights. The antibody can be widely applied to the fields of flow cytometry detection, immunohistochemistry, tumor immunotherapy monitoring and T cell function research, and has important scientific research and clinical application values.

This application relates to an immunohistochemistry humidifier with precise and stable internal humidity. Specifically, an air pump and a humidity sensor are installed inside the humidifier. The air pump circulates air within the humidifier, causing the humidity inside to rise rapidly. The humidity sensor detects the humidity level inside the humidifier. Together, these two components enable the humidifier to quickly reach an ideal humidity environment, thereby improving the quality of sample processing and ensuring the accuracy of subsequent experimental or detection results.

Breast cancer is a serious type of cancer that affects many women each year, often leading to death. To choose the right treatment for breast cancer, studying biomarkers is crucial, and one way to do this is by using the immunohistochemical technique (IHC). Biomarkers like Estrogen receptor (ER), progesterone receptor (PR), Ki67, and P53 play a crucial role in determining the prognosis, progression, and response to treatment of breast cancer. Specific monoclonal antibodies against these biomarkers were created by immunizing mice with peptides derived from these proteins. These antibodies were then tested for specificity using ELISA and IHC staining on normal and cancerous tissues, confirming their ability to recognize the receptors. Additionally, the antibodies were evaluated for isotype, affinity constant, and their ability to detect natural antigens in flow cytometry and western blot.

This invention relates to a reagent management method, system, and apparatus for immunohistochemistry. The method includes the following steps: parsing a set of barcode information obtained by scanning multiple reagent bottles placed on multiple reagent positions in a reagent basket to obtain reagent information for each reagent bottle; associating and binding the reagent information with the current reagent position to establish a position mapping relationship; receiving a dosage adjustment instruction for a specified immunohistochemistry step, obtaining the adjusted dosage parameters, and storing them in a database along with the corresponding reagent identification information; obtaining a list of target reagent types and target reagent dosages required for the current experimental procedure; determining whether the reagents already used meet the experimental requirements based on the position mapping relationship, reagent data information, and the current remaining quantity of each reagent; if not, outputting a warning message; if yes, calculating the estimated reagent quantity for this experiment and updating the remaining quantity information of the corresponding reagents in the database in real time during the experiment.

This invention provides a method for preparing N-terminal Gly2-myristylated ARF1 antibody for immunohistochemical experiments. The method involves immunizing animals with a polypeptide whose amino acid sequence is shown in SEQ ID NO.2 to obtain the ARF1 antibody. The ARF1 antibody prepared by this method can be used in immunohistochemical experiments.

This invention provides a multiplex fluorescence immunohistochemistry method. The method employs a horseradish peroxidase (HRP)-labeled primary antibody in combination with an HRP inactivating agent, avoiding multiple rounds of elution and counterstaining of tissue sections. This shortens the process and time, enabling simultaneous multiplex fluorescence labeling of five or more color channels within two days, and achieving single-cell resolution for single-cell segmentation.

The application relates to the technical field of digital pathology and artificial intelligence, in particular to an immunohistochemical efficacy prediction system based on dynamic analysis. The system comprises an image processing module, which is used for acquiring and preprocessing paired immunohistochemical digital pathology sections before and after treatment of the same patient; a dynamic registration and analysis module, which is used for high-precision image registration of the paired sections and extraction of dynamic quantitative parameters of biomarker expression changes with treatment; a spatial heterogeneity quantification module, which is used for dividing tumor functional subareas and quantifying spatial distribution heterogeneity parameters of biomarkers in different functional subareas; and a fusion prediction module, which is used for feature fusion of the dynamic quantitative parameters and the spatial distribution heterogeneity parameters and output of a clinical efficacy prediction result through a survival analysis model. The system realizes accurate prediction of tumor immunotherapy efficacy by performing dynamic and quantitative analysis on paired immunohistochemical sections before and after treatment and integrating multi-modal data.

This invention relates to a method, apparatus, electronic device, and storage medium for quality control of digital immunohistochemical slides, and pertains to the field of computer vision. The method involves: acquiring morphological images of a first channel and colorimetric images of a second channel; extracting environmental features to determine candidate analysis regions; screening local negative reference regions and mapping them to the second channel to construct a local dynamic baseline; identifying abnormal interference regions and calculating their differences relative to the baseline; generating local staining determination results and local threshold compensation data based on the differences and abnormal interference regions, and dynamically correcting a preset determination threshold to generate a corrected determination threshold; identifying and verifying candidate control regions within a preset control search area for control verification; and fusing local staining state determination results, local dynamic baselines, corrected determination thresholds, abnormal interference, and control verification results to generate whole-slide-level quality control results. This invention improves the reliability of quality control and reduces physical interference from complex microenvironments.

This invention relates to the field of biomedical technology, specifically disclosing a recombinant rabbit monoclonal antibody against human CD3, its preparation method, and its applications. This antibody, obtained by immunizing rabbits to elicit an anti-CD3 immune response, is derived through single-cell B-cell sorting, gene cloning, and a mammalian cell expression system, exhibiting high affinity and good specificity. The antibody can effectively recognize CD3-positive T cells in human peripheral blood and can be applied in flow cytometry, immunohistochemistry, and T cell function studies. Experimental results show that this antibody has advantages such as high titer, strong fluorescence signal, and low background, outperforming traditional murine anti-CD3 antibodies. Further, the amino acid sequences of the variable regions of the light and heavy chains of this antibody were obtained, enabling controllable and reproducible antibody expression. This antibody has significant scientific research value and promising industrial applications, suitable for various scenarios such as T cell marker detection, immune status assessment, and adjuvant research in immunotherapy.

The application discloses an immunohistochemical multi-channel incubation heating device and a temperature error optimization design method, and belongs to the medical detection field.The application utilizes internal wiring of a heating film integrated with a temperature sensor to realize four-wire output of the temperature sensor;analog multiplexing switches are adopted to poll and switch the input of the multi-channel temperature sensor, so that the multi-channel shares the same constant current source driving circuit, instrument amplification circuit and analog-digital conversion circuit;the constant current source drives the temperature sensor to generate a differential voltage signal, which is amplified by an instrument amplifier and then converted into a digital signal by an ADC, and real-time resistance values are calculated according to Ohm's law;based on a pre-stored thermal resistance scale, the minimum interval where the resistance value is located is determined by a table lookup method, and the corresponding temperature value is converted by using a linear equation fitted by interval endpoints;PWM modulation signals are output by a PID algorithm to drive the heating film to realize accurate temperature control.The application eliminates the problem that reference parameters are inconsistent due to the discreteness of electronic components when each channel is independently collected.

This invention relates to the field of biomedicine, specifically to CAR-T therapy targeting solid tumors. It primarily involves antibody panning to identify ScFv cells specifically targeting B7-H3, then designing different CAR-T structures by combining them with chimeric antigen receptors. The indications for solid tumors (including but not limited to lung cancer and ovarian cancer) are determined through in vitro functional validation and in vivo pharmacodynamic evaluation. Simultaneously, its activity and applications in different detection methods (including but not limited to pathological immunohistochemistry and flow cytometry) are verified.

This invention discloses an antigen for inducing polyclonal antibodies against pigeon circovirus Rep protein, comprising the amino acid sequence shown in SEQ ID NO.2, as well as the coding gene of the antigen, an expression vector for the coding gene, a primer pair for the coding gene, and the polyclonal antibody against pigeon circovirus Rep protein. The polyclonal antibody provided by this invention specifically reacts with pigeon circovirus in pigeon tissues, exhibiting good reactivity, and can be applied to molecular biology research related to the identification of pigeon circovirus, such as immunoblotting, immunohistochemistry, or immunofluorescence techniques.